메뉴 건너뛰기
Oscotec Inc.
Translating science into medicine
로그인 유지
ID/PW 찾기
회원가입
로그인
회원가입
로그인
HOME
COMPANY
About Us
History
Members
Contact Us
PIPELINE
Pipeline Overview
Rheumatoid arthritis
Immune thrombocytopenia
Acute myeloid leukemia
Non-small cell lung cancer
Alzheimer's disease
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Shareholder Notice
PRESS
주주님들께 드리는 글
2022.08.30
SCI Journal - SKI-G-8...
2022.02.16
FLT3/AXL Inhibitor (A...
2020.06.22
HOME
COMPANY
About Us
History
Members
Contact Us
PIPELINE
Pipeline Overview
Rheumatoid arthritis
Immune thrombocytopenia
Acute myeloid leukemia
Non-small cell lung cancer
Alzheimer's disease
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Shareholder Notice
×
WELCOME
로그인 유지
ID/PW 찾기
×
LANGUAGE : 한국어
English
NEWSROOM
Notice
Press Releases
Publications
IR Materials
Notice
Press Releases
Publications
IR Materials
NEWSROOM
- Notice
- Press Releases
- Publications
- IR Materials
Home
NEWSROOM
Press Releases
T
기본글꼴
기본글꼴
✔
나눔고딕
✔
맑은고딕
✔
돋움
✔
✔
사이트를 뷰어로 보기
검색
Write
Title+내용
Title
내용
Comment
이름
닉네임
아이디
태그
검색
List
Zine
Gallery
INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs
Date
2016-08-23
Media
Scrip (Informa Pharma Intelligence)
Pipeline
Oscotec
Read More
Oscotec wins exception policy for continued R&D for new drugs
Date
2019-06-25
Media
KBR (; Korea Biomedical Review)
Pipeline
Oscotec
Read More
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Date
2021-03-02
Media
CISION
Pipeline
Oscotec
Read More
Other news to note for March 2, 2021
Date
2021-03-02
Media
BioWorld
Pipeline
Oscotec
Read More
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
Date
2023-09-14
Media
Biospace
Pipeline
Oscotec
Read More
Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease
Date
2024-02-23
Media
yahoo! finance
Pipeline
Oscotec
Read More
G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
Date
2014-04-03
Media
PubMed
Pipeline
SKI-G-801
Read More
Oscotec shares rebound on launch of US clinical trial
Date
2017-12-11
Media
KBR (; Korea Biomedical Review)
Pipeline
SKI-G-801
Read More
Oscotec`s acute leukemia treatment wins orphan drug status from FDA
Date
2018-11-23
Media
KBR (; Korea Biomedical Review)
Pipeline
SKI-G-801
Read More
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models
Date
2019-07-01
Media
CANCER RESEARCH
Pipeline
SKI-G-801
Read More
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Date
2019-11-04
Media
Molecular Cancer
Pipeline
SKI-G-801
Read More
Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money
Date
2016-01-19
Media
Scrip (Informa Pharma Intelligence)
Pipeline
SYK-O-703
Read More
Board Pagination
Prev
1
2
3
Next
/ 3
GO
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
서버에 요청 중입니다. 잠시만 기다려 주십시오...